


Express Mail Label No.: EV 392131507 US  
Date of Deposit: August 18, 2004

Attorney Docket No.: 23239-531 CIP



8/19/04 PFW  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS : Stanton, et al.  
SERIAL NUMBER : 10/826,077 EXAMINER : Not Yet Assigned  
FILING DATE : April 15, 2004 ART UNIT : 1645  
FOR : APTAMER-TOXIN MOLECULES AND METHODS FOR USING  
SAME

**Mail Stop Amendment**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages), in duplicate; and
3. Return Postcard.


If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-531 CIP. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

For R. Elrifi, Reg. No. 39,529  
Jennifer A. Karnakis, Reg. No. 53,097  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
Customer No. 30623

Date: August 18, 2004



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS : Stanton, et al.  
SERIAL NUMBER : 10/826,077 EXAMINER : Not Yet Assigned  
FILING DATE : April 15, 2004 ART UNIT : 1645  
FOR : APTAMER-TOXIN MOLECULES AND METHODS FOR USING  
SAME

**Mail Stop Amendment**

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. Copies of the references are not provided as they were previously cited and submitted to the USPTO in a prior application, Serial No. 10/600,007, filed June 18, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the

APPLICANTS: Stanton, et al.  
U.S.S.N.: 10/826,077

information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-531 CIP.

Respectfully submitted,




Ivor R. Elrifi, Reg. No. 39,529  
Jennifer A. Karnakis, Reg. No. 53,097  
Attorneys for Applicants  
c/o MINTZ, LEVIN  
One Financial Center  
Boston, Massachusetts 02111  
Tel: (617) 542-6000  
Fax: (617) 542-2241  
**Customer No. 30623**

Date: August 18, 2004

TRA 1949429v1

Please type a plus sign (+) in this box



Modified Form 1449/2-00 AUG 18 2004 <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)	Application Number	10/826,077
	Filing Date	April 15, 2004
	First Named Inventor	Stanton
	Group Art Unit	1645
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	23239-531 CIP

**U.S. PATENT DOCUMENTS**

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	5,589,332	12/31/96	Shih, et al.	435	6	
	*A2	5,683,867	11/04/97	Biesecker, et al.	435	6	
	*A3	5,705,337	01/06/98	Gold, et al.	435	6	
	*A4	5,723,594	03/03/98	Janjic, et al.	536	23.1	
	*A5	5,834,186	11/10/98	George, et al.	435	6	
	*A6	6,083,696	07/04/00	Biesecker, et al.	435	6	
	*A7	6,232,071 B1	05/15/01	Hicke, et al.,	435	6	

**U.S. PUBLISHED APPLICATION DOCUMENTS**

Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A8	2002/0034506 A1	03/21/02	Pietras, et al.	424	94.63	

**FOREIGN PATENT DOCUMENTS**

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	Translation No
	*B1	WO 98/08974	INTELLIGENE LTD.	03/05/98		
	*B2	WO 98/27104	YALE UNIVERSITY	06/25/98		
	*B3	WO 99/31276	NEXSTAR PHARMACEUTICALS, INC.	06/24/99		
	*B4	WO 00/70329	BRANDEIS UNIVERSITY	11/23/00		
	*B5	WO 01/66721 A2	RIBOZYME PHARMACEUTICALS, INC.	09/13/01		
	*B6	WO 02/22882 A2	ARCHEMIX CORPORATION	03/21/02		
	*B7	WO 03/014375 A2	ARCHEMIX CORPORATION	02/20/03		

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C1	Breaker, R.R., <i>Curr. Opin. Biotech.</i> , 7:442-448 (1996).
	*C2	Breaker, R.R., <i>Chem. Rev.</i> , 97:371-390 (1997).
	*C3	Breaker, R.R., <i>Curr. Opin. Chem. Biol.</i> , 1:26-31 (1997).
	*C4	Breaker, R.R., <i>Nat. Biotech.</i> , 15:427-431 (1997).
	*C5	Breaker, R.R., Intracellular Ribozyme Applications in Principles and Protocols, pgs. 1-19; Horizon Scientific Press, Wymondham UK, Rossi and Couture, eds., (1999).
	*C6	Breaker, R.R., <i>Curr. Opin. Biotech.</i> , 13:31-39 (2002).
	*C7	Carmi, et al. <i>Chem. &amp; Biol.</i> , 3:1039-1046 (1996).
	*C8	Gold, L., <i>Nat. Biotech.</i> , 20: 671-672 (2002).
	*C9	Hamaguchi, et al., <i>Anal. Biochem.</i> , 294:126-131 (2001).

*C10	Hartig, et al., <i>Nat. Biotech.</i> , 20:717-722 (2002).
*C11	Jenne, et al., <i>Nat. Biotech.</i> , 19:56-61 (2001).
*C12	Koizumi, et al., <i>Nucl. Acids Symp. Ser.</i> , 42:275-276 (1999).
*C13	Koizumi, et al., <i>Nat. Struct. Biol.</i> , 6(11):1062-1071 (1999).
*C14	Lewis, et al., <i>Bioconjug. Chem.</i> , 12(2):320-324 (2001).
*C15	Li, et al., <i>Curr. Opin. Struct. Biol.</i> , 9:315-323 (1999).
*C16	Li, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 96:2746-2751 (1999).
*C17	Marshall, et al., <i>Nat. Struct. Biol.</i> , 6(11):992-994 (1999).
*C18	Potyrailo, et al., <i>Anal. Chem.</i> , 70:3419-3425 (1998).
*C19	Raddatz, et al., <i>Nucl. Acids Res.</i> , 30(21):4793-4802 (2002).
*C20	Robertson, et al., <i>Nucl. Acids Res.</i> , 28(8):1751-1759 (2000).
*C21	Robertson, et al., <i>Nat. Biotech.</i> , 17:62-66 (1999).
*C22	Robertson, et al., <i>Nat. Biotech.</i> , 19:650-655 (2001).
*C23	Sassanfar, et al., <i>Nature</i> , 364:550-553 (1993).
*C24	Seetharaman, et al., <i>Nat. Biotech.</i> , 19:336-341 (2001).
*C25	Seiwert, et al., <i>Chem. &amp; Biol.</i> , 7:833-843 (2000).
*C26	Soukup, et al., <i>Proc. Natl. Acad. Sci. USA</i> , 96:3584-3589 (1999).
*C27	Soukup, et al., <i>RNA</i> , 5:1308-1325 (1999).
*C28	Soukup, et al., <i>Structure</i> , 7(7):783-791 (1999).
*C29	Soukup, et al., <i>Tren. Biotech.</i> , 17:469-476 (1999).
*C30	Soukup, et al., in <i>Ribozyme Biochem. Biotech.</i> , Eaton Publishing, Chapter 8, pgs. 149-170, Krupp & Gaur, eds.
*C31	Soukup, et al., <i>RNA</i> , 7:524-536 (2001).
*C32	Soukup, et al., <i>J. Mol. Biol.</i> , 298:623-632 (2000).
*C33	Stetsenko, et al., <i>Nucleosides, Nucleotides &amp; Nucl. Acids</i> , 19(10-12):1751-1764 (2000).
*C34	Tang, et al., <i>Chem. &amp; Biol.</i> , 4:453-459 (1997).
*C35	Tang, et al., <i>Nucl. Acids Res.</i> , 26(18):4214-4221 (1998).
*C36	Tang, et al., <i>RNA</i> , 3:914-925 (1997).
*C37	Trail, et al., <i>Cancer Immunol. Immunother.</i> , 52(5):328-337 (2003).
*C38	Tung, C.H., <i>Bioconjug. Chem.</i> , 11(5):605-618 (2000).

A copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/600,007, filed June 18, 2003, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.